Who
Gregory Austin Ciongoli
Director
Company insider
Files Form 4 as: Director, Gossamer Bio; Director, Regenxbio; Director and 10% owner and Other, Atara Biotherapeutics; Director, Zymeworks.
In numbers
- Trades disclosed
- 18
- Buys
- 2
- Sells
- 0
- Bought
- $1.9M
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 11 Aug 2025
- Last trade
- 23 Sep 2026
- Last filed
- 25 Sep 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 25 Sep 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 27 Aug 2026filed 27 Aug 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Bought | $500K53,407 at $9.36 | filing |
| 27 Aug 2026filed 27 Aug 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Bought | $500K53,407 at $9.36 | filing |
| 26 Aug 2026filed 27 Aug 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Bought | $450K49,196 at $9.14 | filing |
| 26 Aug 2026filed 27 Aug 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Bought | $450K49,196 at $9.14 | filing |
| 25 Aug 2026filed 27 Aug 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —15,432 at $0.00 | filing |
| 25 Aug 2026filed 27 Aug 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —69,609 at $0.00 | filing |
| 25 Aug 2026filed 27 Aug 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —69,609 at $0.00 | filing |
| 25 Aug 2026filed 27 Aug 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —15,432 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,500 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,700 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,500 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,700 at $0.00 | filing |
| 12 Aug 2025filed 12 Aug 2025 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code A | $5.0M415,000 at $12.02 | filing |
| 11 Aug 2025filed 12 Aug 2025 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.